Logo image of PEPG

PEPGEN INC (PEPG) Stock Fundamental Analysis

NASDAQ:PEPG - Nasdaq - US7133171055 - Common Stock

2.05  -0.03 (-1.44%)

Fundamental Rating

3

PEPG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While PEPG has a great health rating, there are worries on its profitability. PEPG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PEPG had negative earnings in the past year.
In the past year PEPG has reported a negative cash flow from operations.
In the past 5 years PEPG always reported negative net income.
PEPG had a negative operating cash flow in each of the past 5 years.
PEPG Yearly Net Income VS EBIT VS OCF VS FCFPEPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

PEPG has a Return On Assets (-51.24%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -63.46%, PEPG is in line with its industry, outperforming 58.23% of the companies in the same industry.
Industry RankSector Rank
ROA -51.24%
ROE -63.46%
ROIC N/A
ROA(3y)-35.25%
ROA(5y)-31.14%
ROE(3y)-43.83%
ROE(5y)-37.08%
ROIC(3y)N/A
ROIC(5y)N/A
PEPG Yearly ROA, ROE, ROICPEPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

PEPG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PEPG Yearly Profit, Operating, Gross MarginsPEPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

PEPG has more shares outstanding than it did 1 year ago.
PEPG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PEPG Yearly Shares OutstandingPEPG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M
PEPG Yearly Total Debt VS Total AssetsPEPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

PEPG has an Altman-Z score of -1.75. This is a bad value and indicates that PEPG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PEPG (-1.75) is comparable to the rest of the industry.
There is no outstanding debt for PEPG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.75
ROIC/WACCN/A
WACCN/A
PEPG Yearly LT Debt VS Equity VS FCFPEPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

PEPG has a Current Ratio of 8.47. This indicates that PEPG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PEPG (8.47) is better than 74.16% of its industry peers.
PEPG has a Quick Ratio of 8.47. This indicates that PEPG is financially healthy and has no problem in meeting its short term obligations.
PEPG has a Quick ratio of 8.47. This is in the better half of the industry: PEPG outperforms 74.34% of its industry peers.
Industry RankSector Rank
Current Ratio 8.47
Quick Ratio 8.47
PEPG Yearly Current Assets VS Current LiabilitesPEPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PEPG have decreased by -8.79% in the last year.
EPS 1Y (TTM)-8.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PEPG will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.06% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.34%
EPS Next 2Y8.16%
EPS Next 3Y4.36%
EPS Next 5Y9.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PEPG Yearly Revenue VS EstimatesPEPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
PEPG Yearly EPS VS EstimatesPEPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PEPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PEPG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PEPG Price Earnings VS Forward Price EarningsPEPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PEPG Per share dataPEPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.16%
EPS Next 3Y4.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PEPG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PEPGEN INC

NASDAQ:PEPG (1/22/2025, 10:45:52 AM)

2.05

-0.03 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners83.52%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap66.83M
Analysts83.64
Price Target12.24 (497.07%)
Short Float %2.34%
Short Ratio3.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.66%
Min EPS beat(2)-18.14%
Max EPS beat(2)25.45%
EPS beat(4)3
Avg EPS beat(4)11.19%
Min EPS beat(4)-18.14%
Max EPS beat(4)25.45%
EPS beat(8)6
Avg EPS beat(8)15.52%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.73%
PT rev (3m)-38.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.11%
EPS NY rev (1m)0%
EPS NY rev (3m)10.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA N/A
EPS(TTM)-2.97
EYN/A
EPS(NY)-2.74
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.53
OCFYN/A
SpS0
BVpS4.22
TBVpS4.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.24%
ROE -63.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.25%
ROA(5y)-31.14%
ROE(3y)-43.83%
ROE(5y)-37.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.47
Quick Ratio 8.47
Altman-Z -1.75
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.55%
Cap/Depr(5y)260.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y12.34%
EPS Next 2Y8.16%
EPS Next 3Y4.36%
EPS Next 5Y9.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.71%
OCF growth 3YN/A
OCF growth 5YN/A